Edelfosine is the prototype molecule of a family of anticancer drugs collectively known as
synthetic alkyl-lysophospholipids. This drug holds promise as a selective antitumor agent …

Edelfosine, an alkyl-lysophospholipid antitumor drug with severe side-effects, has previously
been encapsulated into lipid nanoparticles (LN) with the purpose of improving their toxicity …

Breast cancer is a heterogeneous group of neoplasms predominantly originating in the
terminal duct lobular units. It represents the leading cause of cancer death in women and the …

Background: Lipid nanoparticles (LNs) made of synthetic lipids Compritol® 888 ATO and
Precirol® ATO 5 were developed with an average size of 110.4±2.1 and 103.1±2.9 nm, and …

The ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, edelfosine (ET-18-
OCH3) is the prototype molecule of a promising class of antitumor drugs named alkyl …

Metastasis is the leading cause of cancer mortality. Metastatic cancer is notoriously difficult
to treat, and it accounts for the majority of cancer-related deaths. The ether lipid edelfosine is …

Osteosarcoma (OS) is the most frequent paediatric bone cancer, responsible for 9% of all
cancer-related deaths in children. In this paper, a new strategy based on delivering …

Purpose: The present study investigates and compares the dose-dependent
pharmacokinetics and oral bioavailability of edelfosine in healthy, immunodeficient, and …

The anti-tumor agent edelfosine represents a promising option in the treatment of cancer
due to its capacity of promoting apoptosis in tumor cells selectively, while sparing healthy …

Osteosarcoma (OS) is the most frequent primary malignant bone tumor in the pediatric
population. Current treatments are not able to slow the progression of the disease in patients …